novo nordisk new glp 1 Nordisk's Wegovy pill launch draws wave of patients to GLP-1s Novo Nordisk Reports Positive Test

Smith RG, et al

In a clinical trial, participants who took oral Wegovy lost 13.6% of their total body weight on average over about 15 months, compared with a 2.2% loss if they took a placebo, or dummy pill

For peptides prone to oxidation, minimize air exposure during mixing and consider nitrogen purging if your lab setup allows

The increased use of spironolactone, especially in heart failure patients, has led to an increased number of cases of hyperkalemia

"Some patients do very well at lower doses of drugs, notes Dr

Some arent very stable, so they will lose effectiveness when exposed to light, heat, or air in general